替雷利珠单抗联合阿帕替尼治疗晚期胃癌的效果观察  

Observation on the Effect of Tirelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer

作　　者：闫睿[1] 闫桂芳[2] YAN Rui;YAN Guifang(Department of Oncology,Jiyuan Tumor Hospital,Jiyuan 459000,China;Second Department of Internal Medicine,Jiyuan Second People's Hospital,Jiyuan 459000,China)

机构地区：[1]济源市肿瘤医院肿瘤内科,河南济源459000 [2]济源市第二人民医院内二科,河南济源459000

出　　处：《临床医学工程》2024年第2期161-162,共2页Clinical Medicine & Engineering

摘　　要：目的 分析替雷利珠单抗联合阿帕替尼治疗晚期胃癌的临床效果。方法 78例晚期胃癌患者随机分为两组,对照组采用阿帕替尼治疗,观察组采用替雷利珠单抗联合阿帕替尼治疗,比较两组的疾病控制情况、肿瘤标志物水平以及不良反应。结果 观察组的DCR为84.62%,高于对照组的61.54%(P <0.05)。治疗后,两组的CA125、 CEA水平均低于治疗前(P <0.05),观察组的CA125、 CEA水平均低于对照组(P <0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 替雷利珠单抗联合阿帕替尼治疗晚期胃癌可显著提升疾病控制率,降低患者的CA125、 CEA水平,且未明显增加不良反应的发生。Objective To analyze the clinical effect of tirelizumab combined with apatinib in the treatment of advanced gastric cancer.Methods A total of 78 patients with advanced gastric cancer were randomly divided into two groups.The control group was treated with apatinib,and the observation group was treated with tirelizumab combined with apatinib.The disease control,tumor marker levels and adverse reactions were compared between the two groups.Results The DCR of the observation group was 84.62%,higher than 61.54% of the control group(P <0.05).After treatment,the levels of CA125 and CEA in the two groups were lower than those before treatment(P <0.05),and the levels of CA125 and CEA in the observation group were lower than those in the control group(P <0.05).No significant difference was found in the total incidence of adverse reactions between the two groups(P >0.05).Conclusions Tirelizumab combined with apatinib in the treatment of advanced gastric cancer can significantly improve the disease control rate and reduce the levels of CA125 and CEA of patients,without significant increase of the occurrence of adverse reactions.

关 键 词：替雷利珠单抗 阿帕替尼 晚期胃癌 肿瘤标志物 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]